AstraZeneca’s Farxiga gets FDA breakthrough status in CKD

This article was originally published here

Farxiga is an oral, once-daily sodium-glucose co-transporter-2 inhibitor (SGLT2 inhibitor). Its breakthrough therapy designation in chronic kidney disease was driven by the findings of phase 3 DAPA-CKD trial.

The post AstraZeneca’s Farxiga gets FDA breakthrough status in CKD appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply